Rosalind Advisors Inc. purchased a new stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 870,000 shares of the company's stock, valued at approximately $9,266,000. UroGen Pharma comprises 4.6% of Rosalind Advisors Inc.'s holdings, making the stock its 8th biggest holding. Rosalind Advisors Inc. owned about 3.71% of UroGen Pharma at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. RTW Investments LP increased its position in shares of UroGen Pharma by 6.5% in the 3rd quarter. RTW Investments LP now owns 3,787,347 shares of the company's stock valued at $48,099,000 after acquiring an additional 230,000 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of UroGen Pharma by 1.6% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,341,072 shares of the company's stock valued at $17,032,000 after purchasing an additional 21,072 shares during the period. State Street Corp increased its holdings in shares of UroGen Pharma by 5.9% in the third quarter. State Street Corp now owns 769,583 shares of the company's stock valued at $9,774,000 after purchasing an additional 42,907 shares during the period. Geode Capital Management LLC raised its stake in shares of UroGen Pharma by 8.1% in the third quarter. Geode Capital Management LLC now owns 455,637 shares of the company's stock worth $5,787,000 after purchasing an additional 34,248 shares during the last quarter. Finally, Vestal Point Capital LP acquired a new stake in shares of UroGen Pharma during the third quarter worth about $5,080,000. Institutional investors and hedge funds own 91.29% of the company's stock.
Insider Activity at UroGen Pharma
In related news, insider Mark Schoenberg sold 4,551 shares of UroGen Pharma stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the sale, the insider now owns 145,666 shares of the company's stock, valued at approximately $1,622,719.24. This trade represents a 3.03 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Jason Drew Smith sold 7,379 shares of the business's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now directly owns 26,468 shares of the company's stock, valued at approximately $294,853.52. The trade was a 21.80 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on URGN shares. LADENBURG THALM/SH SH started coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They set a "buy" rating and a $31.00 price target for the company. HC Wainwright reduced their target price on shares of UroGen Pharma from $64.00 to $55.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. Finally, D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 price target on shares of UroGen Pharma in a report on Monday, March 10th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $38.20.
Check Out Our Latest Stock Report on URGN
UroGen Pharma Stock Performance
Shares of NASDAQ:URGN traded up $0.12 during trading on Wednesday, hitting $11.52. 435,649 shares of the stock traded hands, compared to its average volume of 489,831. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The company has a fifty day moving average price of $10.60 and a two-hundred day moving average price of $11.53. UroGen Pharma Ltd. has a 52-week low of $9.03 and a 52-week high of $20.70. The company has a market cap of $531.00 million, a price-to-earnings ratio of -3.66 and a beta of 1.12.
UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). The business had revenue of $24.57 million for the quarter, compared to the consensus estimate of $25.25 million. As a group, equities analysts predict that UroGen Pharma Ltd. will post -3.12 EPS for the current year.
UroGen Pharma Company Profile
(
Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Recommended Stories
Before you consider UroGen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.
While UroGen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
